Skip to content

Compare Hemodynamic Effect of Oxytocin Bolus and Infusion During Cesarean Section Under Spinal Anesthesia

STUDY OF EFFECT OF HEMODYNAMIC CHANGES CAUSED BY OXYTOCIN DURING CESAREAN SECTION UNDER SPINAL ANESTHESIA: COMPARISON BETWEEN INTRAVENOUS BOLUS AND INFUSION TECHNIQUE

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07687355
Enrollment
262
Registered
2026-07-07
Start date
2026-07-01
Completion date
2026-10-01
Last updated
2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comparing 2 Techniques of iv Oxytocin Causing Hemodynamic Changes

Keywords

Oxytocin bolus, Oxytocin nfusion technique, Blood pressure changes by oxytocin, Oxytocin in cesarean section

Brief summary

Oxytocin is routinely used during a cesarean section to promote uterine contraction and prevent postpartum hemorrhage. It is typically administered immediately after delivery of the baby, either as a slow intravenous bolus followed by a continuous infusion or as an infusion alone, depending on clinical protocols. By stimulating the uterine muscles to contract, oxytocin helps reduce blood loss and facilitates uterine involution. Care is taken to avoid rapid high-dose administration, as this may lead to side effects such as hypotension and tachycardia

Detailed description

The administration of Oxytocin during cesarean section under Spinal anesthesia is associated with significant hemodynamic changes, and these effects differ depending on whether the drug is given as an intravenous bolus or as a controlled infusion. Oxytocin causes vasodilation and decreases systemic vascular resistance, which can lead to hypotension, reflex tachycardia, and occasionally nausea or flushing-effects that are often exaggerated under spinal anesthesia due to pre-existing sympathetic blockade. When given as a rapid IV bolus (e.g., 5-10 IU), there is a sudden drop in blood pressure and a marked increase in heart rate, sometimes accompanied by transient myocardial ischemia in susceptible patients. In contrast, administering oxytocin as a slow infusion (e.g., 10-40 IU diluted in IV fluids over time) results in more gradual hemodynamic changes, with better stability of blood pressure and heart rate. Comparative studies have consistently shown that infusion regimens are associated with fewer adverse cardiovascular effects while still providing adequate uterine contraction. Therefore, current clinical practice favors low-dose slow bolus followed by infusion, or infusion alone, to minimize hemodynamic instability while effectively preventing postpartum hemorrhage.

Interventions

5IU OXYTOCIN diluted in 5ml normal saline, given as bolus over 5 second

Sponsors

Hayatabad Medical Complex
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

Women within age range 18-40 Years Women undergoing caesarian with oxytocin under spinal anesthesia as defined in the operational definition.

Exclusion criteria

Women with placenta praevia Women with ruptured membranes Women with hypertensive disorders or diabetes mellitus Women on immunosuppressant

Design outcomes

Primary

MeasureTime frameDescription
Heart rate and blood pressure changes in beats per minute and mmHg respectively by comparing intravenous bolus and infusion oxytocin during Cesarean section under spinal anesthesiaOver period of giving the drug and after 2 to 5 mins of giving drugComparison of iv bolus and infusion technique of oxytocin causing changes hemodynamic are noticed while it is given to patient undergoing Cesarean section under spinal anesthesia

Contacts

CONTACTDr Navishta Sahar Arif Trainee medical officer, MBBS
lailo_dr@yahoo.com+923333493330
PRINCIPAL_INVESTIGATORDr Navishta Sahar Arif, Trainee medical officer, MBBS

PGMI/ Hayatabad medical complex, peshawar

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026